Abstract
Aerosol delivery of asthma medications maximizes local effects in the lung and minimizes systemic effects compared with oral therapy. Both corticosteroids and bronchodilators are available in a variety of delivery devices for the treatment of asthma. The 1987 Montreal protocol requiring the phasing out of the chlorofluorocarbon (CFC) propellant in commonly used pressurized metered-dose inhalers (pMDIs) provided an impetus for the development of new technologies for the delivery of inhaled asthma medications. For pMDIs, CFC has been replaced with hydrofluoroalkane (HFA) propellant. New types of dry powder inhalers (DPIs) and nebulizers, aerosol delivery devices that do not use propellants, also have been introduced. Drug delivery varies based on the device type, the product formulation and patient-related factors. Thus, drug delivery can differ when the same medication is delivered via an HFA pMDI, a CFC pMDI, a DPI or a nebulizer. Even among the same type of device (eg. DPIs, pMDIs), inhaler designs and drug formulations differ. Drug and device selection should be based on consideration of the patients ability to use the device properly, the availability of a desired drug or drugs (ie. maintenance and rescue) in a particular inhaler device and patient preference. This review describes key characteristics for each device type, explains differences in markers of lung deposition, lists potential advantages and disadvantages of the different devices and discusses how these and other factors need to be considered when selecting an inhaler device that meets the individual needs of a patient.
Keywords: aerosol devices, asthma therapy, pMDI, MDI, HFA, nebulizers
Current Drug Delivery
Title: Aerosol Devices and Asthma Therapy
Volume: 6 Issue: 1
Author(s): William Berger
Affiliation:
Keywords: aerosol devices, asthma therapy, pMDI, MDI, HFA, nebulizers
Abstract: Aerosol delivery of asthma medications maximizes local effects in the lung and minimizes systemic effects compared with oral therapy. Both corticosteroids and bronchodilators are available in a variety of delivery devices for the treatment of asthma. The 1987 Montreal protocol requiring the phasing out of the chlorofluorocarbon (CFC) propellant in commonly used pressurized metered-dose inhalers (pMDIs) provided an impetus for the development of new technologies for the delivery of inhaled asthma medications. For pMDIs, CFC has been replaced with hydrofluoroalkane (HFA) propellant. New types of dry powder inhalers (DPIs) and nebulizers, aerosol delivery devices that do not use propellants, also have been introduced. Drug delivery varies based on the device type, the product formulation and patient-related factors. Thus, drug delivery can differ when the same medication is delivered via an HFA pMDI, a CFC pMDI, a DPI or a nebulizer. Even among the same type of device (eg. DPIs, pMDIs), inhaler designs and drug formulations differ. Drug and device selection should be based on consideration of the patients ability to use the device properly, the availability of a desired drug or drugs (ie. maintenance and rescue) in a particular inhaler device and patient preference. This review describes key characteristics for each device type, explains differences in markers of lung deposition, lists potential advantages and disadvantages of the different devices and discusses how these and other factors need to be considered when selecting an inhaler device that meets the individual needs of a patient.
Export Options
About this article
Cite this article as:
Berger William, Aerosol Devices and Asthma Therapy, Current Drug Delivery 2009; 6 (1) . https://dx.doi.org/10.2174/156720109787048203
DOI https://dx.doi.org/10.2174/156720109787048203 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Inflammation Biomarkers in Psychiatry
Current Psychiatry Research and Reviews The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia
Current Neurovascular Research The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia
Current Pharmaceutical Design Cytokine-Directed Therapy in Asthma
Current Drug Targets - Inflammation & Allergy Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Severe Asthma: Why do Some Children Not Respond to Treatment?
Current Pediatric Reviews Past, Present and Future of Electroanalytical Sensor for Aspirin, Ibuprofen and Paracetamol Detection
Current Pharmaceutical Analysis Bispidine as a Privileged Scaffold
Current Topics in Medicinal Chemistry In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid
Current Neuropharmacology The Association Between Obstructive Sleep Apnea and Allergic Rhinitis: Current Literature Review
Current Respiratory Medicine Reviews A Molecular Guidance System Based Upon Target Genes, Nuclear Receptors and Ligands Applied to Drug Discovery and Prediction of Toxicity
Mini-Reviews in Medicinal Chemistry Dietary Assumption of Plant Polyphenols and Prevention of Allergy
Current Pharmaceutical Design Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease
Current Alzheimer Research Antagonism of Eosinophil Accumulation in Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Anti-inflammatory Lipid Mediators Derived from ω-6 and ω-3 Polyunsaturated Fatty Acids as a Treatment Option for IBD
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Advances in Drug Discovery to Assess Cholinergic Neurotransmission: A Systematic Review
Current Drug Discovery Technologies